List of Acceleron Pharma patents

Patents where

Current Assignee

Name

Acceleron Pharma

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11440949 TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof		Acceleron Pharma	Acceleron Pharma	United States Patent and Trademark Office	11440949	September 13, 2022
‌ US Patent 10358476 Single arm type I and type II receptor fusion proteins and uses thereof	Patent 10358476 was granted and assigned to Acceleron Pharma on July, 2019 by the United States Patent and Trademark Office.	Acceleron Pharma	Acceleron Pharma	United States Patent and Trademark Office	10358476	July 23, 2019
‌ US Patent 11318188 Compositions and methods for treating pulmonary hypertension	Patent 11318188 was granted and assigned to Acceleron Pharma on May, 2022 by the United States Patent and Trademark Office.	Acceleron Pharma	Acceleron Pharma	United States Patent and Trademark Office	11318188	May 3, 2022
‌ US Patent 11622992 Compositions and methods for treating pulmonary hypertension	Patent 11622992 was granted and assigned to Acceleron Pharma on April, 2023 by the United States Patent and Trademark Office.	Acceleron Pharma	Acceleron Pharma	United States Patent and Trademark Office	11622992	April 11, 2023
‌ US Patent 11497794 Compositions and methods for treating pulmonary hypertension		Acceleron Pharma	Acceleron Pharma	United States Patent and Trademark Office	11497794	November 15, 2022
‌ US Patent 9884900 Methods for treating Janus kinase-associated disorders by administering soluble transforming growth factor beta type II receptor	Patent 9884900 was granted and assigned to Acceleron Pharma on February, 2018 by the United States Patent and Trademark Office.	Acceleron Pharma	Acceleron Pharma	United States Patent and Trademark Office	9884900	February 6, 2018
‌ US Patent 8138142 Methods for increasing adiponectin in a patient in need thereof	Patent 8138142 was granted and assigned to Acceleron Pharma on March, 2012 by the United States Patent and Trademark Office.		Acceleron Pharma	United States Patent and Trademark Office	8138142	March 20, 2012
‌ US Patent 11059894 ALK7 binding proteins and uses thereof	Patent 11059894 was granted and assigned to Acceleron Pharma on July, 2021 by the United States Patent and Trademark Office.		Acceleron Pharma	United States Patent and Trademark Office	11059894	July 13, 2021
‌ US Patent 11279746 ALK4:ActRIIB heteromultimers and uses thereof		Acceleron Pharma	Acceleron Pharma	United States Patent and Trademark Office	11279746	March 22, 2022
‌ US Patent 11028145 ALK7:actriib heteromultimers and uses thereof	Patent 11028145 was granted and assigned to Acceleron Pharma on June, 2021 by the United States Patent and Trademark Office.	Acceleron Pharma	Acceleron Pharma	United States Patent and Trademark Office	11028145	June 8, 2021
‌ US Patent 7709605 ActRII receptor polypeptides, methods and compositions	Patent 7709605 was granted and assigned to Acceleron Pharma on May, 2010 by the United States Patent and Trademark Office.		Acceleron Pharma	United States Patent and Trademark Office	7709605	May 4, 2010
‌ US Patent 8178488 Methods for increasing thermogenic adipocytes	Patent 8178488 was granted and assigned to Acceleron Pharma on May, 2012 by the United States Patent and Trademark Office.		Acceleron Pharma	United States Patent and Trademark Office	8178488	May 15, 2012
‌ US Patent 10259861 Variants derived from ActRIIB and uses therefor	Patent 10259861 was granted and assigned to Acceleron Pharma on April, 2019 by the United States Patent and Trademark Office.	Acceleron Pharma	Acceleron Pharma	United States Patent and Trademark Office	10259861	April 16, 2019
‌ US Patent 9399669 Variants derived from ActRIIB	Patent 9399669 was granted and assigned to Acceleron Pharma on July, 2016 by the United States Patent and Trademark Office.	Acceleron Pharma	Acceleron Pharma	United States Patent and Trademark Office	9399669	July 26, 2016
‌ US Patent 7842663 Variants derived from ActRIIB and uses therefor	Patent 7842663 was granted and assigned to Acceleron Pharma on November, 2010 by the United States Patent and Trademark Office.		Acceleron Pharma	United States Patent and Trademark Office	7842663	November 30, 2010
‌ US Patent 8343933 Variants derived from ActRIIB and uses therefor	Patent 8343933 was granted and assigned to Acceleron Pharma on January, 2013 by the United States Patent and Trademark Office.		Acceleron Pharma	United States Patent and Trademark Office	8343933	January 1, 2013
‌ US Patent 10189882 Methods for treating myelodysplastic syndromes and sideroblastic anemias	Patent 10189882 was granted and assigned to Acceleron Pharma on January, 2019 by the United States Patent and Trademark Office.	Acceleron Pharma	Acceleron Pharma	United States Patent and Trademark Office	10189882	January 29, 2019
‌ US Patent 8252900 Actriib-Fc polynucleotides, polypeptides, and compositions	Patent 8252900 was granted and assigned to Acceleron Pharma on August, 2012 by the United States Patent and Trademark Office.		Acceleron Pharma	United States Patent and Trademark Office	8252900	August 28, 2012
‌ US Patent 7612040 Lefty polypeptides and derivatives thereof	Patent 7612040 was granted and assigned to Acceleron Pharma on November, 2009 by the United States Patent and Trademark Office.		Acceleron Pharma	United States Patent and Trademark Office	7612040	November 3, 2009
‌ US Patent 10377996 Methods of identifying ActRIIB variants	Patent 10377996 was granted and assigned to Acceleron Pharma on August, 2019 by the United States Patent and Trademark Office.	Acceleron Pharma	Acceleron Pharma	United States Patent and Trademark Office	10377996	August 13, 2019
‌ US Patent 7456149 ALK7 and myostatin inhibitors and uses thereof	Patent 7456149 was granted and assigned to Acceleron Pharma on November, 2008 by the United States Patent and Trademark Office.		Acceleron Pharma	United States Patent and Trademark Office	7456149	November 25, 2008
‌ US Patent 9138459 ACTRIIB-FC polynucleotides, polypeptides, and compositions	Patent 9138459 was granted and assigned to Acceleron Pharma on September, 2015 by the United States Patent and Trademark Office.		Acceleron Pharma	United States Patent and Trademark Office	9138459	September 22, 2015
‌ US Patent 10358633 Method for producing an ActRIIB-Fc fusion polypeptide	Patent 10358633 was granted and assigned to Acceleron Pharma on July, 2019 by the United States Patent and Trademark Office.	Acceleron Pharma	Acceleron Pharma	United States Patent and Trademark Office	10358633	July 23, 2019
‌ US Patent 9617319 ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy	Patent 9617319 was granted and assigned to Acceleron Pharma on April, 2017 by the United States Patent and Trademark Office.	Acceleron Pharma	Acceleron Pharma	United States Patent and Trademark Office	9617319	April 11, 2017
‌ US Patent 9181533 Truncated ACTRIIB-FC fusion protein	Patent 9181533 was granted and assigned to Acceleron Pharma on November, 2015 by the United States Patent and Trademark Office.	Acceleron Pharma	Acceleron Pharma	United States Patent and Trademark Office	9181533	November 10, 2015

...

Results per page:

149 results

0 selected

149 results

0 selected